Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTASXS1654

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	STN Patent Forums to be held in June 2005
NEWS	20	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	21	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	22	JUN 13	FRFULL enhanced with patent drawing images
NEWS	23	JUN 20	MEDICONF to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:35:43 ON 21 JUN 2005

=> set cluster
ENTER CLUSTER NAME OR (?):.biotech
ENTER LIST OF FILE NAMES OR (?):medline,biosis,biotechds,caplus,embase
MORE FILES, (NONE) OR ?:.
CLUSTER '.BIOTECH' DEFINED AS 'MEDLINE, BIOSIS, BIOTECHDS, CAPLUS, EMBASE'
SET COMMAND COMPLETED

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.84	0.84

FILE 'REGISTRY' ENTERED AT 15:37:49 ON 21 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUN 2005 HIGHEST RN 852602-49-4
DICTIONARY FILE UPDATES: 20 JUN 2005 HIGHEST RN 852602-49-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> e melagatran

E1	1		MELAFOLONE/BI
E2	1		MELAFORM/BI
E3	3	-->	MELAGATRAN/BI
E4	3		MELAIN/BI
E5	691		MELAL/BI
E6	2		MELALEUC/BI
E7	662		MELALEUCA/BI
E8	6		MELALEUCAE/BI
E9	1		MELALEUCATE/BI
E10	6		MELALEUCIC/BI
E11	2		MELALEUCOIDES/BI
E12	1		MELALEUCOL/BI

```
=> s e3
L1             3 MELAGATRAN/BI

=> d rn cn

L1   ANSWER 1 OF 3  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   303184-53-4  REGISTRY
CN   Glycine, N-[(1R)-2-[(2S)-2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]car
     bonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-, ethyl ester (9CI)  (CA
     INDEX NAME)
OTHER NAMES:
CN   Ethyl melagatran
CN   Melagatran ethyl ester


=> file .biotech
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   7.73       8.57

FILE 'MEDLINE' ENTERED AT 15:39:30 ON 21 JUN 2005

FILE 'BIOSIS' ENTERED AT 15:39:30 ON 21 JUN 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 15:39:30 ON 21 JUN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CAPLUS' ENTERED AT 15:39:30 ON 21 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:39:30 ON 21 JUN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

=> stem cell#
STEM IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s stem cell#
L2         233461 STEM CELL#

=> s islet(1w)langerhan#
L3          20728 ISLET(1W) LANGERHAN#

=> s insulin(2a)produc?(2a)cell#
   4 FILES SEARCHED...
L4           5183 INSULIN(2A) PRODUC?(2A) CELL#

=> s pancrea?(2a)cell#
L5          92240 PANCREA?(2A) CELL#

=> s melagatran
L6            981 MELAGATRAN

=> s 303184-53-4
L7             13 303184-53-4

=> s kit
L8          90874 KIT
```

```
=> s therap?
L9     6946706 THERAP?

=> s treat?diabet?
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'TREAT?DIABET?'
The truncation symbol ?  may be used only at the end of a search
term.  To specify a variable character within a word use '!', e.g.,
'wom!n' to search for both 'woman' and 'women'.  Enter "HELP
TRUNCATION" at an arrow prompt (=>) for more information.

=> s treat?
COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> s diabet?
L10     798226 DIABET?

=> s medicament#
L11      23810 MEDICAMENT#

=> s l2-l5 and l6 and l8-l9
   4 FILES SEARCHED...
L12          4 (L2 OR L3 OR L4 OR L5) AND L6 AND (L8 OR L9)

=> s l2-l5 and l7 and l8-l9
   4 FILES SEARCHED...
L13          0 (L2 OR L3 OR L4 OR L5) AND L7 AND (L8 OR L9)

=> d ibib l12

L12  ANSWER 1 OF 4  EMBASE  COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN
ACCESSION NUMBER:   2005003566  EMBASE
TITLE:              Novel constructs for thrombin inhibition.
AUTHOR:             Becker R.C.
CORPORATE SOURCE:   becke021@mc.duke.edu
SOURCE:             American Heart Journal, (2005) Vol. 149, No. 1 SUPPL., pp.
                    S61-S72.
                    Refs: 56
                    ISSN: 0002-8703  CODEN: AHJOA2
PUBLISHER IDENT.:   S 0002-8703(04)00777-X
COUNTRY:            United States
DOCUMENT TYPE:      Journal; General Review
FILE SEGMENT:       018     Cardiovascular Diseases and Cardiovascular Surgery
                    025     Hematology
                    030     Pharmacology
                    037     Drug Literature Index
                    038     Adverse Reactions Titles
LANGUAGE:           English
SUMMARY LANGUAGE:   English
ENTRY DATE:         Entered STN: 20050113
                    Last Updated on STN: 20050113


=> d ibib l12 all

L12  ANSWER 1 OF 4  EMBASE  COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN
ACCESSION NUMBER:   2005003566  EMBASE
TITLE:              Novel constructs for thrombin inhibition.
AUTHOR:             Becker R.C.
CORPORATE SOURCE:   becke021@mc.duke.edu
SOURCE:             American Heart Journal, (2005) Vol. 149, No. 1 SUPPL., pp.
```

S61-S72.
Refs: 56
ISSN: 0002-8703 CODEN: AHJOA2

PUBLISHER IDENT.: S 0002-8703(04)00777-X
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery
025 Hematology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20050113
Last Updated on STN: 20050113

AN 2005003566 EMBASE
TI Novel constructs for thrombin inhibition.
AU Becker R.C.
CS becke021@mc.duke.edu
SO American Heart Journal, (2005) Vol. 149, No. 1 SUPPL., pp. S61-S72.
Refs: 56
ISSN: 0002-8703 CODEN: AHJOA2
PUI S 0002-8703(04)00777-X
CY United States
DT Journal; General Review
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
025 Hematology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 20050113
Last Updated on STN: 20050113
AB Inhibiting thrombin, whether directly, indirectly, or by preventing its generation and biological activity, is scientifically attractive and achievable. Currently available compounds will provide an opportunity to define the degree and duration of modulation required to suppress thrombin-mediated inflammatory, mitogenic, and prothrombotic responses. The restoration of normal endothelial function and thromboresistance using cell-based, molecular, and/or combined pharmacologic and cell-specific **therapeutics** may well be the most desirable area for investigation. Regardless of the chosen approach, treatments will require a design that acknowledges the dynamic nature of atherothrombosis, individual variation in thrombotic capacity and drug response, and the importance of regulability.
CT Medical Descriptors:
*anticoagulation
enzyme inhibition
bleeding: SI, side effect
heart infarction: DT, drug therapy
heart infarction: PC, prevention
coronary artery disease: DT, drug therapy
drug blood level
stem cell
dose response
cell based gene therapy
human
nonhuman
clinical trial
review
priority journal
Drug Descriptors:
*thrombin inhibitor: AE, adverse drug reaction
*thrombin inhibitor: CT, clinical trial

*thrombin inhibitor: CM, drug comparison
*thrombin inhibitor: CR, drug concentration
*thrombin inhibitor: DO, drug dose
***thrombin inhibitor: DT, drug therapy**
*thrombin inhibitor: TO, drug toxicity
*thrombin inhibitor: IV, intravenous drug administration
*thrombin inhibitor: PO, oral drug administration
*thrombin inhibitor: PK, pharmacokinetics
*thrombin inhibitor: PD, pharmacology
*thrombin inhibitor: SC, subcutaneous drug administration
*blood clotting factor 10a inhibitor: IV, intravenous drug administration
*blood clotting factor 10a inhibitor: PD, pharmacology
hirudin: CM, drug comparison
hirudin: IV, intravenous drug administration
hirudin: PD, pharmacology
enoxaparin: CM, drug comparison
enoxaparin: DT, drug therapy
enoxaparin: PD, pharmacology
melagatran: CR, drug concentration
melagatran: TO, drug toxicity
melagatran: PK, pharmacokinetics
melagatran: PD, pharmacology
melagatran: SC, subcutaneous drug administration
ximelagatran: AE, adverse drug reaction
ximelagatran: CT, clinical trial
ximelagatran: CM, drug comparison
ximelagatran: DO, drug dose
ximelagatran: DT, drug therapy
ximelagatran: TO, drug toxicity
ximelagatran: PO, oral drug administration
ximelagatran: PK, pharmacokinetics
ximelagatran: PD, pharmacology
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid: AE, adverse drug reaction
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid: CT, clinical trial
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid: CB, drug combination
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid: CR, drug concentration
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid: DO, drug dose
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid: DT, drug therapy
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid: IV, intravenous drug administration
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid: PK, pharmacokinetics
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid: PD, pharmacology
clopidogrel: CT, clinical trial
clopidogrel: CB, drug combination
clopidogrel: DT, drug therapy
acetylsalicylic acid: CT, clinical trial
acetylsalicylic acid: CB, drug combination
acetylsalicylic acid: DT, drug therapy
fibrinogen receptor antagonist: CT, clinical trial
fibrinogen receptor antagonist: CB, drug combination
fibrinogen receptor antagonist: DT, drug therapy
heparin: CT, clinical trial
heparin: CM, drug comparison
heparin: DT, drug therapy
sr 123781a: CM, drug comparison
sr 123781a: DO, drug dose
sr 123781a: IV, intravenous drug administration

sr 123781a: PD, pharmacology
aptamer: DO, drug dose
aptamer: PD, pharmacology
unclassified drug

RN (hirudin) 8001-27-2; (enoxaparin) 9041-08-1; (**melagatran**) 159776-70-2; (ximelagatran) 192939-46-1, 260790-58-7; (2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid) 155204-81-2; (clopidogrel) 113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8; (acetylsalicylic acid) 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; (heparin) 37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5

CN Dx 9065a; Sr 123781a

=> d l12 1-4 ibib abs kwic

L12 ANSWER 1 OF 4 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2005003566 EMBASE
TITLE: Novel constructs for thrombin inhibition.
AUTHOR: Becker R.C.
CORPORATE SOURCE: becke021@mc.duke.edu
SOURCE: American Heart Journal, (2005) Vol. 149, No. 1 SUPPL., pp. S61-S72.
Refs: 56
ISSN: 0002-8703 CODEN: AHJOA2
PUBLISHER IDENT.: S 0002-8703(04)00777-X
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery
025 Hematology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20050113
Last Updated on STN: 20050113

AB Inhibiting thrombin, whether directly, indirectly, or by preventing its generation and biological activity, is scientifically attractive and achievable. Currently available compounds will provide an opportunity to define the degree and duration of modulation required to suppress thrombin-mediated inflammatory, mitogenic, and prothrombotic responses. The restoration of normal endothelial function and thromboresistance using cell-based, molecular, and/or combined pharmacologic and cell-specific **therapeutics** may well be the most desirable area for investigation. Regardless of the chosen approach, treatments will require a design that acknowledges the dynamic nature of atherothrombosis, individual variation in thrombotic capacity and drug response, and the importance of regulability.

AB . . . mitogenic, and prothrombotic responses. The restoration of normal endothelial function and thromboresistance using cell-based, molecular, and/or combined pharmacologic and cell-specific **therapeutics** may well be the most desirable area for investigation. Regardless of the chosen approach, treatments will require a design that. . .

CT Medical Descriptors:
*anticoagulation
enzyme inhibition
bleeding: SI, side effect
heart infarction: DT, drug therapy
heart infarction: PC, prevention
coronary artery disease: DT, drug therapy
drug blood level
stem cell

dose response
cell based gene therapy
human
nonhuman
clinical trial
review
priority journal
*thrombin inhibitor: AE, adverse drug reaction
*thrombin inhibitor: CT, clinical trial
*thrombin inhibitor: CM, drug comparison
*thrombin inhibitor: CR, drug concentration
*thrombin inhibitor: DO, drug dose
***thrombin inhibitor: DT, drug therapy**
*thrombin inhibitor: TO, drug toxicity
*thrombin inhibitor: IV, intravenous drug administration
*thrombin inhibitor: PO, oral drug administration
*thrombin inhibitor: PK,. . . intravenous drug administration
*blood clotting factor 10a inhibitor: PD, pharmacology
hirudin: CM, drug comparison
hirudin: IV, intravenous drug administration
hirudin: PD, pharmacology
enoxaparin: CM, drug comparison
enoxaparin: DT, drug therapy
enoxaparin: PD, pharmacology
melagatran: CR, drug concentration
melagatran: TO, drug toxicity
melagatran: PK, pharmacokinetics
melagatran: PD, pharmacology
melagatran: SC, subcutaneous drug administration
ximelagatran: AE, adverse drug reaction
ximelagatran: CT, clinical trial
ximelagatran: CM, drug comparison
ximelagatran: DO, drug dose
ximelagatran: DT, drug therapy
ximelagatran: TO, drug toxicity
ximelagatran: PO, oral drug administration
ximelagatran: PK, pharmacokinetics
ximelagatran: PD, pharmacology
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3. . . amidino 2 naphthyl)propionic acid: CR, drug concentration
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid: DO, drug dose
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid: DT, drug therapy
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3. . . PK, pharmacokinetics
2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid: PD, pharmacology
clopidogrel: CT, clinical trial
clopidogrel: CB, drug combination
clopidogrel: DT, drug therapy
acetylsalicylic acid: CT, clinical trial
acetylsalicylic acid: CB, drug combination
acetylsalicylic acid: DT, drug therapy
fibrinogen receptor antagonist: CT, clinical trial
fibrinogen receptor antagonist: CB, drug combination
fibrinogen receptor antagonist: DT, drug therapy
heparin: CT, clinical trial
heparin: CM, drug comparison
heparin: DT, drug therapy
sr 123781a: CM, drug comparison
sr 123781a: DO, drug dose
sr 123781a: IV, intravenous drug administration
sr 123781a: PD, pharmacology
aptamer: DO,. . .

RN (hirudin) 8001-27-2; (enoxaparin) 9041-08-1; (**melagatran**) 159776-70-2; (ximelagatran) 192939-46-1, 260790-58-7; (2 [4 [(1 acetimidoyl 3 pyrrolidinyl)oxy]phenyl] 3 (7 amidino 2 naphthyl)propionic acid) 155204-81-2; (clopidogrel) 113665-84-2, 120202-66-6,. . .

L12 ANSWER 2 OF 4 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2004517046 EMBASE
TITLE: Blasts from the past.
AUTHOR: Insel P.A.; Kornfeld S.; Majerus P.W.; Marks A.R.; Marks P.A.; Relman A.S.; Scharschmidt B.F.; Stossel T.P.; Varki A.P.; Weiss S.J.; Wilson J.D.
CORPORATE SOURCE: P.A. Insel, 630 West 168th Street, New York, NY 10032, United States. editors@the-jci.org
SOURCE: Journal of Clinical Investigation, (2004) Vol. 114, No. 8, pp. 1017-1033.
Refs: 114
ISSN: 0021-9738 CODEN: JCINAO
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
016 Cancer
018 Cardiovascular Diseases and Cardiovascular Surgery
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20041228
Last Updated on STN: 20041228

AB With this issue of the JCI, we celebrate the 80th anniversary of the Journal. While 80 years is not a century, we still feel it is important to honor what the JCI has meant to the biomedical research community for 8 decades. To illustrate why the JCI is the leading general-interest translational research journal edited by and for biomedical researchers, we have asked former JCI editors-in-chief to reflect on some of the major scientific advances reported in the pages of the Journal during their tenures.

CT Medical Descriptors:
*medical research
cell aging
ketoacidosis
brain function
starvation
gallstone
hyperlipidemia
heart infarction: DT, drug therapy
growth disorder
fibrinolytic therapy
thrombus: DT, drug therapy
drug efficacy
coronary artery thrombosis: DT, drug therapy
heart hypertrophy
hypertension
glucose intolerance
glomerulopathy: DT, drug therapy
glomerulopathy: ET, etiology
atherosclerosis: DT, drug therapy
atherosclerosis: ET, etiology
thrombosis: DT, drug therapy
thrombosis: PC, prevention
inflammatory disease
phagocytosis
pneumonia: DT, drug therapy
juvenile rheumatoid arthritis: DT, drug therapy
tumor vascularization

Tangier disease: ET, etiology
drug safety
enteritis
preeclampsia
pancreas cancer: DT, drug therapy
pancreas cell
stem cell transplantation
diabetes mellitus: DT, drug therapy
diabetes mellitus: TH, therapy
human
nonhuman
clinical trial
review
priority journal
alteplase: CT, clinical trial
alteplase: DT, drug therapy
alteplase: PD, pharmacology
glucagon: CB, drug combination
glucagon: PD, pharmacology
adrenalin: CB, drug combination
adrenalin: PD, pharmacology
oral antidiabetic agent: PO, oral drug. . . antidiabetic agent: PD, pharmacology
tolbutamide: CB, drug combination
tolbutamide: IV, intravenous drug administration
tolbutamide: PD, pharmacology
urokinase
streptokinase
monoclonal antibody: PD, pharmacology
integrin alpha2beta3: PD, pharmacology
integrin: PD, pharmacology
enalapril: DT, drug therapy
enalapril: PD, pharmacology
prostaglandin synthase inhibitor
antiinflammatory agent: PD, pharmacology
interleukin 8: PD, pharmacology
antioxidant: CT, clinical trial
antioxidant: DT, drug therapy
vasculotropin inhibitor
heparin: CT, clinical trial
heparin: CM, drug comparison
heparin: DT, drug therapy
heparin: PD, pharmacology
thrombin inhibitor: CT, clinical trial
thrombin inhibitor: CM, drug comparison
thrombin inhibitor: DT, drug therapy
thrombin inhibitor: PO, oral drug administration
thrombin inhibitor: PD, pharmacology
hirudin: CT, clinical trial
hirudin: CM, drug comparison
hirudin: DT, drug therapy
hirudin: PD, pharmacology
argatroban
hirulog
melagatran
ximelagatran: PO, oral drug administration
leptin: CV, intracerebroventricular drug administration
leptin: PD, pharmacology
interleukin 6 antibody: CT, clinical trial
interleukin 6 antibody: DT, drug therapy
interleukin 6 antibody: PD, pharmacology
tumor necrosis factor related apoptosis inducing ligand: PD, pharmacology
metformin: DT, drug therapy
metformin: PO, oral drug administration
metformin: PD, pharmacology

2,4 thiazolidinedione derivative
antineoplastic agent: CB, drug combination
antineoplastic agent: PD, pharmacology
unindexed drug
unclassified drug
imatinib
bevacizumab
semaxanib
2,4. . .

RN. . . (urokinase) 139639-24-0; (streptokinase) 9002-01-1; (enalapril) 75847-73-3; (interleukin 8) 114308-91-7; (heparin) 37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5; (hirudin) 8001-27-2; (argatroban) 74863-84-6; (hirulog) 128270-60-0; (**melagatran**) 159776-70-2; (ximelagatran) 192939-46-1, 260790-58-7; (metformin) 1115-70-4, 657-24-9; (imatinib) 152459-95-5, 220127-57-1; (bevacizumab) 216974-75-3; (semaxanib) 186610-95-7; (2,4 dimethyl 5 (2 oxo 1h. . .

L12 ANSWER 3 OF 4 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2004510055 EMBASE
TITLE: Protecting **pancreatic** β- **cells.**
AUTHOR: Pileggi A.; Fenjves E.S.; Klein D.; Ricordi C.; Pastori R.L.
CORPORATE SOURCE: Dr. R.L. Pastori, Diabetes Research Institute, Univ. of Miami School of Medicine, 1450 NW 10th Avenue, Miami, FL 33136, United States. rpastori@med.miami.edu
SOURCE: IUBMB Life, (2004) Vol. 56, No. 7, pp. 387-394.
Refs: 70
ISSN: 1521-6543 CODEN: IULIF8
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 029 Clinical Biochemistry
048 Gastroenterology
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20041217
Last Updated on STN: 20041217

AB Type 1 diabetes mellitus is an autoimmune disorder in which the **insulin-producing** β- **cells** of the **pancreatic** islets of Langerhans are selectively destroyed. Transplantation of allogeneic islets offers a novel **therapeutic** approach for type 1 diabetic patients. Primary obstacles to the successful outcome of this treatment are loss of the islets occurring first during the isolation procedure and then immediately following transplantation. The genetic make up of β-cells contributes to making them particularly vulnerable to apoptosis and necrosis-induced cell death caused by the trauma of the isolation procedure and by non-specific inflammatory events at the transplantation site. In this review we present description of chemical and molecular biology based strategies to confer cytoprotection to β-cells.

TI Protecting **pancreatic** β- **cells.**

AB Type 1 diabetes mellitus is an autoimmune disorder in which the **insulin-producing** β- **cells** of the **pancreatic** islets of Langerhans are selectively destroyed. Transplantation of allogeneic islets offers a novel **therapeutic** approach for type 1 diabetic patients. Primary obstacles to the successful outcome of this treatment are loss of the islets. . .

CT Medical Descriptors:
***pancreas islet beta cell**
*cell protection
insulin dependent diabetes mellitus
autoimmune disease
insulin release
pancreas islet
allogeneic hematopoietic stem cell transplantation

treatment outcome
isolation procedure
genetic analysis
apoptosis
cell death
inflammation
binding site
chemical analysis
molecular biology
gene therapy
gene vector
human
controlled study
human cell
review
calcitriol
estradiol
carbon monoxide
cyclooxygenase 2 inhibitor
glucagon like peptide
somatomedin
lisofylline
dextran
protoporphyrin
melagatran
nicotinamide
peroxisome proliferator activated receptor agonist
pyruvic acid
proteinase inhibitor
superoxide dismutase
hydroxymethylglutaryl coenzyme A reductase inhibitor
endotoxin
scatter factor

RN. . . 32511-63-0, 66772-14-3; (estradiol) 50-28-2; (carbon monoxide) 630-08-0; (glucagon like peptide) 82905-30-4; (lisofylline) 100324-81-0, 151852-32-3, 6493-06-7; (dextran) 87915-38-6, 9014-78-2; (protoporphyrin) 553-12-8; (**melagatran**) 159776-70-2; (nicotinamide) 11032-50-1, 98-92-0; (pyruvic acid) 127-17-3, 19071-34-2, 57-60-3; (proteinase inhibitor) 37205-61-1; (superoxide dismutase) 37294-21-6, 9016-01-7, 9054-89-1; (scatter factor) 67256-21-7,. . .

L12 ANSWER 4 OF 4 EMBASE
on STN

ACCESSION NUMBER: 2003249349 EMBASE
TITLE: Islet cell transplantation as a cure for insulin dependent diabetes: Current improvements in preserving islet cell mass and function.
AUTHOR: Fontaine M.J.; Fan W.
CORPORATE SOURCE: Dr. M.J. Fontaine, Department of Pathology, Medical University of South Carolina, 165 Ashley Ave., Charleston, SC 29425, United States. fontainm@musc.edu
SOURCE: Hepatobiliary and Pancreatic Diseases International, (2003) Vol. 2, No. 2, pp. 170-179.
Refs: 72
ISSN: 1499-3872 CODEN: HPDIAJ
COUNTRY: China
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 003 Endocrinology
009 Surgery
026 Immunology, Serology and Transplantation
037 Drug Literature Index
038 Adverse Reactions Titles
048 Gastroenterology
LANGUAGE: English
SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20030710
Last Updated on STN: 20030710

AB Objective: To review the current progress of islet cell transplantation in patients with insulin-dependent diabetes, emphasizing on the difficulties with recovering and preserving islet cell mass and function, 30% of which is lost during the peri-transplantation period. Results: The islet-cell isolation technique is perfected, but improvements are still progressing in two major directions: preservation of islet cells and tolerance induction. Optimum islet cell viability and function depends on appropriate revascularization of the islet graft and blockade of thrombus formation as well as cytokine and free radical release. Conditioning the islet cells in-vitro prior to transplantation to either upregulate VEGF expression or downregulate NF-kappa B transcription factor has proven to improve revascularization and to prevent islet cell apoptosis and cytokine-mediated damage. Tolerance induction is currently being best achieved by selecting and combining immunosuppressive agents such as monoclonal antibodies which target the major signaling molecules during immune activation, but which are least toxic to islet cells. Conclusions: Patients with insulin-dependent diabetes will greatly benefit from current developments in effective approaches to protect islets during the peritransplant period. Emerging interest in **stem cell** biology and differentiation may provide the ultimate solution to the problem of organ scarcity and islet cell protection from the peritransplant induced damage.

AB . . . diabetes will greatly benefit from current developments in effective approaches to protect islets during the peritransplant period. Emerging interest in **stem cell** biology and differentiation may provide the ultimate solution to the problem of organ scarcity and islet cell protection from the. . .

CT Medical Descriptors:
*insulin dependent diabetes mellitus: SU, surgery
*pancreas islet transplantation
*graft preservation
treatment indication
pancreas islet cell
pancreas islet cell function
perioperative period
cell loss
cell isolation
isolation procedure
immunological tolerance
cell viability
revascularization
vein thrombosis: CO, complication
vein thrombosis: DT, drug therapy
vein thrombosis: PC, prevention
cytokine release
preoperative period
upregulation
protein expression
down regulation
treatment outcome
apoptosis
cell damage
immunosuppressive treatment
drug targeting
signal transduction
immune response
cytotoxicity
cell protection
stem cell
cell differentiation
organ transplantation
graft rejection: CO, complication
graft rejection: DT, drug therapy

graft rejection: PC, prevention
drug potentiation
diabetogenesis
diabetes mellitus: SI, side effect
diabetes mellitus: SU, surgery
human
nonhuman
mouse
review
free radical: EC, endogenous compound
cytokine:. . . agent: AE, adverse drug reaction
immunosuppressive agent: CB, drug combination
immunosuppressive agent: CM, drug comparison
immunosuppressive agent: DO, drug dose
immunosuppressive agent: IT, drug interaction
immunosuppressive agent: DT, drug therapy
immunosuppressive agent: PD, pharmacology
monoclonal antibody: CB, drug combination
monoclonal antibody: DT, drug therapy
monoclonal antibody: PD, pharmacology
steroid: AE, adverse drug reaction
interleukin 2 receptor antibody: CB, drug combination
interleukin 2 receptor antibody: CM, drug comparison
interleukin 2 receptor antibody: DT, drug therapy
interleukin 2 receptor antibody: PD, pharmacology
daclizumab: CB, drug combination
daclizumab: CM, drug comparison
daclizumab: DT, drug therapy
daclizumab: PD, pharmacology
tsukubaenolide: CB, drug combination
tsukubaenolide: CM, drug comparison
tsukubaenolide: DO, drug dose
tsukubaenolide: DT, drug therapy
tsukubaenolide: PD, pharmacology
rapamycin: CB, drug combination
rapamycin: CM, drug comparison
rapamycin: DT, drug therapy
rapamycin: PD, pharmacology
calcineurin inhibitor: AE, adverse drug reaction
calcineurin inhibitor: CB, drug combination
calcineurin inhibitor: CM, drug comparison
calcineurin inhibitor: DT, drug therapy
calcineurin inhibitor: PD, pharmacology
heparin: DT, drug therapy
heparin: PD, pharmacology
melagatran: DT, drug therapy
melagatran: PD, pharmacology
thrombin inhibitor: DT, drug therapy
thrombin inhibitor: PD, pharmacology
tissue factor pathway inhibitor: DT, drug therapy
tissue factor pathway inhibitor: PD, pharmacology
tumor necrosis factor alpha: EC, endogenous compound
gamma interferon: EC, endogenous compound
interleukin 1: EC, endogenous compound
interleukin 4: CB, drug combination
interleukin 4: CM, drug comparison
interleukin 4: IT, drug interaction
interleukin 4: DT, drug therapy
interleukin 4: PD, pharmacology
interleukin 10: CB, drug combination
interleukin 10: CM, drug comparison
interleukin 10: IT, drug interaction
interleukin 10: DT, drug therapy
interleukin 10: PD, pharmacology
cyclosporin A: CB, drug combination

cyclosporin A: CM, drug comparison
cyclosporin A: IT, drug interaction
cyclosporin A: DT, drug therapy
cyclosporin A: PD, pharmacology
nicotinamide: PD, pharmacology
nitric oxide: EC, endogenous compound
nitric oxide synthase inhibitor: PD, pharmacology
aminoguanidine: PD, pharmacology
n(g). . .
RN (vasculotropin) 127464-60-2; (interleukin 2 receptor antibody) 179045-86-4; (tsukubaenolide) 104987-11-3; (rapamycin) 53123-88-9; (heparin) 37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5; (**melagatran**) 159776-70-2; (tissue factor pathway inhibitor) 116638-34-7; (gamma interferon) 82115-62-6; (cyclosporin A) 59865-13-3, 63798-73-2; (nicotinamide) 11032-50-1, 98-92-0; (nitric oxide) 10102-43-9; (aminoguanidine). . .

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	64.80	73.37

STN INTERNATIONAL LOGOFF AT 15:52:03 ON 21 JUN 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTASXS1654

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images